{'fraction_non_alphanumeric': 0.02564102564102564, 'fraction_numerical': 0.011752136752136752, 'mean_word_length': 5.5524475524475525, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Oral Vasoconstrictors in Perennial Non‐Allergic Rhinitis

Nasal airway resistance and nasal symptoms were evaluated in patients with perennial non‐allergic rhinitis before and after vasoconstrictory drugs and placebo taken orally. The patients were partly selected; these suffering mainly from nasal obstruction being tested. Phenylpropanolamine (PPA) in a dose of 100 nig in a sustained‐release preparation clearly decreased the nasal airway resistance measured rhimomanometrically. PPA in a dose of 50 mg and combined with au antihistamine had no obvious decongesting effect. Placebo and dihydroergotamine (DHE) in a dose of 5 mg did not decrease the nasal airway resistance. PPA (100 mg) and the combined preparation containing PPA in the lower dose (50 mg) taken twice a day in across‐over, double‐blind study significantly reduced nasal obstruction, secretion, and sneezing compared with placebo. Side effects of PPA are discussed.